Product News Archives | Page 12 of 15 | Aurobindo Pharma USA

Currently Browsing

All Product News

December 03, 2020


Aurobindo Receives FDA Approval for Ketorolac Tromethamine Ophthalmic Solution, 0.5%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Ketorolac Tromethamine Ophthalmic Solution, 0.5%. Aurobindo Pharma’s Ketorolac Tromethamine Ophthalmic Solution, 0.5% are an AB-rated generic equivalent to the reference listed drug (RLD), Acular® Ophthalmic Solution, 0.5% (Allergan, Inc.) Ketorolac Tromethamine Ophthalmic […]

August 14, 2020


Aurobindo Pharma’s JV, Eugia Pharma receives FDA approval for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg

East Windsor, N.J. – Aurobindo Pharma’s JV, Eugia Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. Aurobindo’s  JV, Eugia Pharma Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. are an AB-rated generic equivalent to the reference listed drug (RLD), Nolvadex® Tablets, […]

August 12, 2020


Aurobindo Receives FDA Approval for Methocarbamol Tablets USP, 750 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Methocarbamol Tablets USP, 750 mg. Aurobindo’s Methocarbamol Tablets USP, 750 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Robaxin-750® Tablets of Auxilium Pharmaceuticals, LLC. Methocarbamol Tablets are indicated for: Indicated as an adjunct […]

August 11, 2020


Aurobindo received FDA Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg.  Aurobindo’s Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg, are an AB-rated generic equivalent to the reference listed drug (RLD), ProAmatine Tablets […]

July 31, 2020


Aurobindo Receives FDA Approval for Anastrozole Tablets USP, 1 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Anastrozole Tablets USP, 1 mg. Aurobindo’s Anastrozole Tablets USP, 1 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Arimidex Tablets, 1 mg, of ANI Pharmaceuticals, Inc. Anastrozole Tablets […]

July 31, 2020


Aurobindo Receives FDA Approval for Imatinib Mesylate Tablets 100 mg and 400 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Imatinib Mesylate Tablets, 100 mg and 400 mg. Aurobindo’s Imatinib Mesylate Tablets, 100 mg and 400 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Gleevec Tablets, 100 mg […]

July 31, 2020


Aurobindo Pharma has received approval for Montelukast Sodium Oral Granules USP, 4mg

East Windsor, NJ–Aurobindo Pharma has received approval from the U.S. Food and Drug Administrationfor its Abbreviated New Drug Application Montelukast Sodium Oral Granules USP, 4mg. Aurobindo’s Montelukast Sodium Oral Granules USP, 4 mg are an AB-rated generic equivalent to the reference listed drug (RLD),SINGULAIR® of Merck & Co Inc. They will be available in 4 […]

April 08, 2020


Aurobindo Pharma has received approval for Tizanidine Hydrochloride capsules

East Windsor, NJ – Aurobindo Pharma has received approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Tizanidine Hydrochloride capsules. Aurobindo’s Tizanidine Hydrochloride capsules are an AB-rated generic that is equivalent to the brand drug Zanaflex® and will be available in 2 mg, 4 mg, and 6 mg dose […]

February 07, 2020


Aurobindo Receives FDA Approval for Methotrexate Tablets USP, 2.5 mg.

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Methotrexate Tablets USP, 2.5 mg. Aurobindo’s Methotrexate Tablets USP, 2.5 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Rheumatrex Tablets, 2.5 mg, of DAVA Pharmaceuticals, Inc. Methotrexate Tablets […]

December 30, 2019


Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Mirtazapine Tablets Lot Number 03119002A3 Due to Label Error on Declared Strength

Aurobindo Pharma USA, Inc. Contact – 1-866-850-2876 option 2 Recall returns being handled by: Qualanex: Contact 1-888-504-2014 FOR IMMEDIATE RELEASE – December 30, 2019 – East Windsor, NJ, Aurobindo Pharma USA, Inc. is voluntarily recalling lot number 03119002A3 of Mirtazapine Tablets to the consumer level. The product is being recalled due to a label error […]